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Once a peanut allergy develops, advice has his-
torically been simple: lifelong complete avoid-
ance is needed to prevent systemic allergic reac-
tions, some of which could be fatal. However, 
over the past decade, a series of case reports and 
small studies have shown that the systematic 
introduction of tiny amounts of peanut allergen, 
followed by gradual increases in dose, could 
prevent or attenuate systemic reactions.1-4 The 
concept gained traction when a group in Cam-
bridge, United Kingdom, found that 12% defatted 
peanut f lour could induce desensitization in 
children.5
Vickery and colleagues now present in the 
Journal6 the results of a randomized, controlled 
trial involving approximately 550 participants 
with peanut allergy. The trial used a Good 
Manufacturing Process–produced 12% defatted 
peanut f lour preparation, known as AR101, as 
the allergen. For the peanut challenges at screen-
ing and trial exit, the authors chose to focus on 
the final tolerated dose (i.e., the dose that could 
be ingested without dose-limiting symptoms). In 
reality, families are interested in how much pea-
nut their child can be exposed to in one meal 
without it inducing symptoms, not the final dose. 
Furthermore, peanuts vary in size and therefore 
in protein content, so translating the doses of 
peanut protein that were used in the trial to the 
equivalent in actual peanuts is difficult. In this 
editorial, I have used the conversion factor that 
was used by Vickery and colleagues — that is, 
that one peanut kernel contains 300 mg of pea-
nut protein (in contrast to the Cambridge group, 
which estimated that one peanut kernel contains 
160 mg of peanut protein). In the primary 
analysis population of children and adolescents 
4 to 17 years of age, after 1 year of treatment 
with AR101, before which they could consume 
less than half a peanut, two thirds of them could 
consume a cumulative dose of approximately 
four peanuts, whereas in the control group only 
1 in 25 participants could consume this amount. 
In the 56 participants older than 17 years of age, 
no effect of AR101 treatment was shown.
Desensitization was not easy on the patients. 
Side effects during the intervention period that 
led to withdrawal from the trial occurred in 
11.6% of the participants in the active-drug 
group and in 2.4% of those in the control group. 
This is not something to start at home. Epineph-
rine was used by 14.0% of the participants in the 
active-drug group as a result of reactions to 
treatment. The longer-term side effects of sus-
tained consumption of an allergen to which the 
body has produced IgE antibodies remain un-
known. Current thinking has focused on eosino-
philic disease, such as eosinophilic esophagitis, 
but surveillance and follow-up will be crucial.
The major concern regarding immunotherapy 
is that the allergen tolerance that is induced will 
be temporary and lost if regular consumption 
ceases. Neither the Cambridge group, nor the in-
vestigators in this trial, have attempted to estab-
lish the duration for which allergen tolerance is 
maintained in the absence of ongoing consump-
tion. Sustained unresponsiveness was claimed in 
an immunotherapy trial conducted by Tang et al.,7 
which also used peanut f lour, but the median 
duration of cessation of consumption was only 
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2.3 weeks — a period that would be better de-
scribed as a brief interruption in therapy rather 
than as sustained cessation. Hence, sustained, 
potentially lifelong, regular consumption may 
be needed to maintain allergen tolerance. Most 
parents would see the regular consumption of a 
few peanuts by their child as a very small price 
to pay to keep the potential threat of systemic 
anaphylaxis at bay.
For the one third of participants who did not 
tolerate the cumulative dose of approximately 
four peanuts during the exit challenge, questions 
remain as to what role, if any, adjunctive therapy 
with, for example, anti-IgE therapy, epicutaneous 
immunotherapy, or probiotics might have in help-
ing these persons benefit from oral desensitiza-
tion. Once the increasing-dose phase is com-
plete, maintenance treatment should continue 
with actual peanuts, as was offered by the Cam-
bridge group when they initially investigated the 
efficacy and safety of their then-new oral immu-
notherapy protocol, which allowed participants 
the choice of receiving their maintenance im-
munotherapy as actual peanuts instead of as 
peanut flour.8
The clinical value of AR101 will be to allow 
the initiation of peanut immunotherapy with a 
product that reliably contains the tiny initial 
quantities of peanut that are required to safely 
launch oral desensitization. The lowest-dose cap-
sules of AR101 contain 0.5 mg and 1 mg of 
peanut protein. In the absence of a product such 
as AR101, it is extremely difficult to administer 
such a small amount of allergen to a patient on 
a consistent basis. The Cambridge group used 
microscales and issued the doses of peanut flour 
in vials. However, errors regarding the initial 
doses during the increasing-dose phase would 
seem to be a more likely occurrence if allergy 
treatment centers all measured their own doses 
of peanut f lour rather than using a carefully 
manufactured product. Furthermore, the issuing 
of peanut flour to a patient with peanut allergy 
may result in the peanut being deemed an un-
licensed medicinal product by regulatory organi-
zations in some countries.9 Once a product such 
as AR101 appears, such regulators will insist 
that a licensed product be used when it is avail-
able, thus preventing the ongoing use of peanut 
flour itself.
AR101 and other, similar products such as 
CA002, which is being developed by the Cam-
bridge group, would therefore appear to have a 
role in initial dose escalation. The potential 
market for these products is believed to be bil-
lions of dollars.10 It is perhaps salutary to con-
sider that in the study conducted by the Cam-
bridge group, children underwent desensitization 
with a bag of peanut flour costing peanuts.
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